NICE favors Harvoni in draft guidance
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has given the green light for Gilead's hepatitis C combination Harvoni (sofosbuvir and ledipasvir) to be used on the NHS, though with several restrictions.